Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immunochemical Colorectal Cancer Test An Accurate Adjunct – Lancet Study

This article was originally published in The Gray Sheet

Executive Summary

The combination of guaiac and immunochemical fecal occult blood testing can reduce the need for colonoscopies by 30%, according to a Lancet study published Jan. 5

You may also be interested in...



Research Sheds Light On Appropriate Frequency And Age For Colonoscopy

Two studies in the May 24 Journal of the American Medical Association provide insight into how frequently colonoscopic cancer screening should occur and the age at which it should be discontinued, but do not get at the more basic question of whether the expensive procedure is effective in reducing colon cancer incidence or deaths, according to an accompanying editorial

Research Sheds Light On Appropriate Frequency And Age For Colonoscopy

Two studies in the May 24 Journal of the American Medical Association provide insight into how frequently colonoscopic cancer screening should occur and the age at which it should be discontinued, but do not get at the more basic question of whether the expensive procedure is effective in reducing colon cancer incidence or deaths, according to an accompanying editorial

TEC Finds iFOBT Test Evidence Lacking In Contrast To Medicare Decision

A 1BlueCross BlueShield Association TEC assessment finding insufficient evidence on the use of immunochemical fecal occult blood tests contradicts a recent positive Medicare national coverage decision

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel